Managing Pain in Patients With Plantar Fasciitis - A Blinded Randomized Controlled Trial

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Terminated
CT.gov ID
NCT06116799
Collaborator
(none)
45
1
3
13.1
3.4

Study Details

Study Description

Brief Summary

Plantar fasciitis (PF), a leading cause of persistent heel pain, results in almost a million physician visits annually. Conservative treatment is often the first line of management with insoles being frequently prescribed. While multiple studies have compared insoles based on the degree of customization to foot contour, the literature is lacking in data comparing insoles based on their material. In this randomized clinical trial, we compared the early effects of polyethylene (PE), polyurethane (PU), and carbon fiber insoles in the treatment of PF, using a set of patient-reported outcomes.

Condition or Disease Intervention/Treatment Phase
  • Device: Orthotic
N/A

Detailed Description

Carbon fiber insoles (VKTRY, Milford, CT, USA) were initially designed to increase ground forces leading to a harder push off for faster running or higher jumping. To enable energy return, the insoles require extreme rigidity and therefore are composed of a full-length carbon-fiber base. The highly rigid construct of the carbon fiber can potentially benefit patients with plantar fasciitis by using these insoles in their own shoes, which could lead to more effective pain management, increased compliance, and improved patient outcomes. While this insole is currently being widely used by athletes, the application of this insole for PF patients has not been explored. Therefore, the aim of this study is to understand how patients respond to the these insoles compared to current standard orthotics (Superfeet Green, Superfeet Worldwide LLC. WA, USA and Aetrex L20, Aetrex Inc, NJ, USA) in a blinded randomized controlled trial.

Study Design

Study Type:
Interventional
Actual Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
19 patients with plantar fasciitis will be allocated to carbon fiber insole group 19 patients with plantar fasciitis will be allocated to polyurethane insole group 19 patients with plantar fasciitis will be allocated to polyethylene insole group19 patients with plantar fasciitis will be allocated to carbon fiber insole group 19 patients with plantar fasciitis will be allocated to polyurethane insole group 19 patients with plantar fasciitis will be allocated to polyethylene insole group
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Managing Pain in Patients With Plantar Fasciitis - A Blinded Randomized Controlled Trial
Actual Study Start Date :
Apr 1, 2022
Actual Primary Completion Date :
May 6, 2023
Actual Study Completion Date :
May 6, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Carbon fiber insole

assigned carbon fiber insole

Device: Orthotic
Arch support orthotic

Active Comparator: Polyurethane

Assigned polyurethane insole

Device: Orthotic
Arch support orthotic

Active Comparator: Polyethylene

assigned polyethylene insole

Device: Orthotic
Arch support orthotic

Outcome Measures

Primary Outcome Measures

  1. PROMIS-Pain interference [Baseline, 2nd-, 6th-, and 12th-week follow-ups]

    measures the extent to which pain hinders an individual's engagement with physical, mental, cognitive, emotional, recreational, and social activities

  2. PROMIS-Pain intensity [Baseline, 2nd-, 6th-, and 12th-week follow-ups]

    assesses how much a person hurts. Patients are usually able to provide quantitative pain intensity estimates relatively quickly

Secondary Outcome Measures

  1. Foot and Ankle Outcome Score [Baseline, 2nd-, 6th-, and 12th-week follow-ups]

    a 42-item questionnaire with 5 subscales: pain (9 items), other symptoms (7 items), activities of daily living (ADL) (17 items), sports/recreation (5 items), and quality of life (4 items

  2. Visual Analogue Scale for pain [Baseline, 2nd-, 6th-, and 12th-week follow-ups]

    A Visual Analogue Scale (VAS) is one of the pain rating scales

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients (over 18 years old) with plantar fasciitis

  • Adults who are competent and able to consent on their own behalf

  • Patients who are seen at MGH Boston, MGH Waltham and Newton Wellesley Hospital

Exclusion Criteria:
  • Patients who received an injection in the last 6 months in their plantar fascia

  • Patients who will need to be treated surgically

  • Patients who are non-English speaking

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Soheil Ashkani Esfahani, Director, Foot and Ankle Research and Innovation Laboratory, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT06116799
Other Study ID Numbers:
  • 2021P003250
First Posted:
Nov 3, 2023
Last Update Posted:
Nov 3, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 3, 2023